Nanotechnology and RNA-Based Technologies Applied to Prophylaxis and Advanced Therapies
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: 10 March 2025 | Viewed by 90
Special Issue Editors
Interests: biotechnology; mRNA; adjuvants; vaccines; therapies
2. Laboratory of Tissue Engineering and Immunopharmacology, Oswaldo Cruz Foundation, Gonçalo Moniz Institute—Fiocruz, Salvador 40296-710, Bahia, Brazil
Interests: biotechnology; mRNA vaccines; mRNA therapeutics; interference RNA; lipid nanoparticles; cancer; infectious diseases; neglected diseases
Special Issue Information
Dear Colleagues,
Various RNA technologies have revolutionized biotechnology by enabling the precise manipulation and understanding of genetic information. Techniques such as RNA interference (RNAi) and CRISPR-Cas9 utilize RNA molecules to target and modify specific genes, offering potential treatments for genetic disorders and cancers. mRNA vaccines, like those developed for COVID-19, showcase the power of RNA in rapidly producing effective vaccines. Overall, RNA technologies are paving the way for innovative therapies, diagnostics, and research tools in biotechnology. This Special Issue aims to cover the aspects of nanotechnology and RNA-based technologies applied to vaccines and treatments, including recent original research or reviews, based on any of the following themes:
- Nanotechnology for RNA applications;
- Lipid nanoparticles for mRNA vaccines and therapies;
- mRNA vaccines and therapies;
- RNA-based advanced therapies;
- RNAi for therapeutics.
We look forward to receiving your contributions.
Prof. Dr. Bruna Aparecida Souza Machado
Dr. Vinicius Pinto Costa Rocha
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- RNA-technologies
- nanotechnology
- messenger RNA (mRNA)
- interference RNA (RNAi)
- vaccines
- treatment
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
